Vorinostat Completed Phase 1 Trials for Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00310024Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma